Anti-IgE Reference Antibody (talizumab)
Référence APR10168
Conditionnement : 100ug
Marque : Abcepta
Anti-IgE Reference Antibody (talizumab)
Recombinant Antibody
Anti-IgE Reference Antibody (talizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Application ![]()
| E |
|---|---|
| Primary Accession | P0DOX4 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 145 KDa |
| Target/Specificity | IgE |
|---|---|
| Endotoxin | < 0.001EU/ µg,determined by LAL method. |
| Conjugation | Unconjugated |
| Expression system | CHO |
| Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.
| Name | IGE |
|---|---|
| Function | Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins- secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268). |
| Cellular Location | Secreted. Cell membrane |
Research Areas
- Primary Antibodies
- Antibody Collections
- Recombinant Antibodies
- Therapeutics References





